Dasatinib (Sprycel®) and Low Intensity Chemotherapy for First-Line Treatment in Patients with De Novo Philadelphia Positive ALL Aged 55 and Over: Final Results of the EWALL-Ph-01 Study
暂无分享，去创建一个
J. Cayuela | H. Dombret | A. Delannoy | S. Hayette | O. Reman | P. Rousselot | P. Agapé | C. Gambacorti-Passerini | J. Ribera | O. Ottmann | E. Jourdan | D. Hoelzer | M. Coudé | C. Berthou | R. Bassan | N. Gökbuget | L. Sutton | A. Banos | M. Hunault | M. Lafage | B. Lioure | F. Huguet | T. Leguay | C. Salanoubat | M. Alexis | J. Fernandes | M. Janvier | S. Giebel | F. Witz | A. Delannoy